MicroVue™ CICP EIA

The MicroVue CICP assay measures type I C-terminal collagen propeptide (CICP) in serum.

Product Specifications

Citations	17
Specimen	Serum 25 μL
LLOQ	1 ng/mL
ULOQ	80 ng/mL
Assay Time	4 hours
Cross Reactivity	Cynomolgous monkey, Rabbit, Rhesus monkey

Technical Documents

Ordering Information

For Research Use Only in the United States. Not for use in diagnostic procedures.

Catalog Number	8005
Catalog Number (CE)	8003
Size	96 wells/test
Price (USD)	$835.00
Price (EURO)	740,00 €

Request an Order

Contact us

US Phone	+1 (858) 552 1100
EU Phone	+353 (91) 412 474
US Email	contact-us@quidelortho.com
EU Email	contact-emea@quidelortho.com

Specifications
Citations
Certificate of Analysis

Specifications

Description	The MicroVue CICP assay measures type I C-terminal collagen propeptide (CICP) in serum.
Size	96 wells/test
Form	96 well plate with 12 eight-well strips in a resealable foil pouch
Specimen	Serum 25 μL
Limit of Detection (LOD)	0.2 ng/mL
Lower Limit of Quantitation (LLOQ)	1 ng/mL
Upper Limit of Quantitation (ULOQ)	80 ng/mL
Intra Assay	5.5–6.8%
Inter Assay	5–7%
Standards	6
Controls	2
Sample Values	Adult: 69–103 ng/mL, Children: 110–966 ng/mL
Assay Time	4 hours
Cross Reactivity	Cynomolgous monkey, Rabbit, Rhesus monkey
Storage	Store unopened kit between 2°C to 8°C. Refer to manual for storing individual components
Background	Collagen, the triple-helical molecule which forms the fibrous framework of all connective tissues, is synthesized as procollagen, a larger precursor molecule. Procollagen consists of mature collagen with extension peptides at both the amino and carboxy termini. These extension peptides, or propeptides, are cleaved from the collagen molecule by specific proteases prior to incorporation of collagen into a growing collagen fibril. The release of these peptides into the circulation provides a stoichiometric representation of the production of collagen.

Citations

Title	Year	Applications	Sample Species	Sample	Sample Details
The shunt from the cyclooxygenase to lipoxygenase pathway in human osteoarthritic subchondral osteoblasts is linked with a variable expression of the 5-lipoxygenase-activating protein.	2006	ELISA	Human	Osteoblasts
Use of small interfering ribonucleic acids to inhibit the adipogenic effect of alcohol on human bone marrow-derived mesenchymal cells.	2010	ELISA	Human	Mesenchymal Cells
Changes in serum collagen markers, IGF-I, and knee joint laxity across the menstrual cycle.	2012	ELISA	Human	Serum
Circulating matrix metalloproteinases in adolescents with hypertrophic cardiomyopathy and ventricular arrhythmia.	2012	ELISA	Human	Plasma
Serum biomarkers of bone metabolism in castration-resistant prostate cancer patients with skeletal metastases: results from SWOG 0421.	2014	ELISA	Human	Serum
Calcipotriol counteracts betamethasone-induced decrease in extracellular matrix components related to skin atrophy.	2014	ELISA	Human	Fibroblasts
Tumor necrosis factor-α-accelerated degradation of type I collagen in human skin is associated with elevated matrix metalloproteinase (MMP)-1 and MMP-3 ex vivo.	2015	ELISA	Human	Skin Tissue
Infection of Human Liver Myofibroblasts by Hepatitis C Virus: A Direct Mechanism of Liver Fibrosis in Hepatitis C.	2015	ELISA	Human	Liver Myofibroblasts	HCV Infected
Negative Effects of Total Gastrectomy on Bone Tissue Metabolism and Volumetric Bone Mineral Density (vBMD) of Lumbar Spine in 1-Year Study in Men.	2016	ELISA	Human	Serum
Circulating LOXL 2 Levels Reflect Severity of Intestinal Fibrosis and GALT CD4 + T Lymphocyte Depletion in Treated HIV Infection.	2017	ELISA	Human	Plasma	HIV
Migration Capacity and Viability of Human Primary Osteoblasts in Synthetic Three-dimensional Bone Scaffolds Made of Tricalciumphosphate.	2011	ELISA	Human	Osteoblasts
New insights into tenocyte-immune cell interplay in an in vitro model of inflammation.	2017	ELISA	Human	Peripheral blood mononuclear cells
Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421.	2018	ELISA	Human	Serum
Re-Differentiation Capacity of Human Chondrocytes in Vitro Following Electrical Stimulation with Capacitively Coupled Fields.	2019	ELISA	Human	Chondrocytes
Modulation of fibroblast inflammatory response by surface modification of a perfluorinated ionomer.	2011	ELISA	N/A	Nafion
Cathepsin K Contributes to Cavitation and Collagen Turnover in Pulmonary Tuberculosis.	2016	ELISA	Rabbit	Plasma
Antifibrotic therapy in simian immunodeficiency virus infection preserves CD4+ T-cell populations and improves immune reconstitution with antiretroviral therapy.	2015	ELISA	Rhesus Monkey	Serum

Certificate of Analysis

Showing results for

No results found for

Legal Notice

By accessing, browsing, and/or using this website, you acknowledge that you have read, understood, and agree to be bound by QuidelOrtho’s Website Terms of Use, Privacy Notice and to comply with all applicable laws and regulations. If you do not agree to these terms, do not use the website. Additionally, the website contains information on products that is targeted to many different audiences and could contain product details or information otherwise not accessible or valid in your country. Product availability may vary from country to country and is subject to varying regulatory requirements. New QuidelOrtho branding may not be available in all markets, subject to country specific regulatory approval. Please be aware that we do not take any responsibility for your accessing such information that may not comply with any legal process, regulation, registration, or usage in the country of your origin.

©2024 QuidelOrtho Corporation. All rights reserved.

QuidelOrtho Corporation
9975 Summers Ridge Road, San Diego, CA 92121, USA